色婷婷狠狠18禁久久YY,一本大道伊人av久久综合,真人作爱90分钟免费看视频,欧美性生交xxxxx无码影院,97人妻免费线观看2018

EN

科研成果

Publications

向下滑動(dòng)

Low-dose radiotherapy promotes the formation of tertiary lymphoid structures in lung adenocarcinoma

發(fā)布時(shí)間:2024.09.06

閱讀次數(shù):372

分享:

點(diǎn)擊下載

Abstract
Purpose: A tertiary lymphoid structure (TLS) refers to an organized infiltration of immune cells that is linked to a positive prognosis and improved response to immunotherapy. However, methods that promote TLS formation are limited and challenging to implement in clinical settings. In this study, we aimed to promote the formation and maturation of TLSs in lung adenocarcinoma (LUAD) by combining low-dose radiotherapy (LDRT) with immunotherapy.

Methods: Tissue sections from 198 patients who had undergone surgery were examined. Risk factors for patient survival were assessed, and the relationship between TLSs and five-year survival was analyzed. The Kras-LSL-G12D spontaneous lung cancer mouse model was used to screen the optimal irradiation dose (0/1/2 Gy whole lung irradiation) for promoting TLS formation. LDRT combined with anti-PD-1 was used to promote the formation and maturation of TLSs.

Results: TLS+, TLSHigh, TLS+GC+ and CD8High within TLS+ were associated with a favorable prognosis. LDRT increased the formation of early TLSs in the Kras-LSL-G12D lung cancer mouse model. In addition, LDRT combined with anti-PD-1 treatment can significantly improve the maturity of TLSs in mouse LUAD, resulting in greater antitumor effects. This antitumor effect was strongly associated with the number of CD8+ T cells within the TLSs.

Conclusion: We successfully applied LDRT combined with PD-1 inhibitor therapy for the first time, which increased both the quantity and maturity of TLSs in lung cancer. This approach achieved a promising antitumor effect.

Keywords: immunotherapy; low dose radiotherapy; lung cancer; tertiary lymphoid structures; tumor microenvironment.

Copyright © 2024 Wang, Huang, Qian, Cao, Wu, Xu, Ming, Tang, Huang, Yin and Zhou.

PubMed Disclaimer

Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright ? 艾克發(fā)(北京)生物技術(shù)有限公司 版權(quán)所有 備案號(hào):京ICP備2021017346號(hào) 網(wǎng)站維護(hù)